NPF
CRL icon

Norris Perne & French’s Charles River Laboratories CRL Stock Holding History

Norris Perne & French’s Portfolio CRL Stock Details CRL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-5,475
Closed -$1.09M – 152
2025
Q4 		$1.09M Sell
5,475
-4,198
-43% -$761K 0.07% 80
2025
Q3 		$1.51M Sell
9,673
-110,649
-92% -$17.6M 0.1% 72
2025
Q2 		$18.3M Sell
120,322
-8,760
-7% -$1.17M 1.27% 33
2025
Q1 		$19.4M Buy
129,082
+3,028
+2% +$508K 1.46% 28
2024
Q4 		$23.3M Sell
126,054
-3,948
-3% -$761K 1.68% 23
2024
Q3 		$25.6M Sell
130,002
-535
-0.4% -$111K 1.76% 18
2024
Q2 		$27M Buy
130,537
+1,907
+1% +$432K 1.95% 13
2024
Q1 		$34.9M Sell
128,630
-3,363
-3% -$803K 2.5% 9
2023
Q4 		$31.2M Buy
131,993
+28,103
+27% +$5.53M 2.41% 10
2023
Q3 		$20.4M Buy
103,890
+1,077
+1% +$221K 1.78% 18
2023
Q2 		$21.6M Buy
102,813
+1,267
+1% +$252K 1.82% 18
2023
Q1 		$20.5M Buy
101,546
+927
+0.9% +$210K 1.88% 16
2022
Q4 		$21.9M Sell
100,619
-2,284
-2% -$499K 2.16% 8
2022
Q3 		$20.3M Buy
102,903
+2,420
+2% +$522K 2.1% 9
2022
Q2 		$21.5M Buy
100,483
+25,343
+34% +$6.19M 2.07% 11
2022
Q1 		$21.3M Buy
75,140
+1,701
+2% +$525K 1.72% 18
2021
Q4 		$27.7M Sell
73,439
-1,397
-2% -$543K 2.15% 8
2021
Q3 		$30.9M Buy
74,836
+315
+0.4% +$131K 2.65% 4
2021
Q2 		$27.6M Sell
74,521
-8,132
-10% -$2.72M 2.38% 6
2021
Q1 		$24M Sell
82,653
-24,934
-23% -$6.93M 2.22% 9
2020
Q4 		$26.9M Sell
107,587
-758
-0.7% -$181K 2.53% 5
2020
Q3 		$24.5M Sell
108,345
-1,263
-1% -$262K 2.67% 7
2020
Q2 		$19.1M Sell
109,608
-1,656
-1% -$264K 2.33% 11
2020
Q1 		$14M Buy
111,264
+12,222
+12% +$1.83M 2.11% 14
2019
Q4 		$15.1M Buy
99,042
+870
+0.9% +$120K 1.81% 17
2019
Q3 		$13M Sell
98,172
-1,958
-2% -$263K 1.62% 20
2019
Q2 		$14.2M Buy
100,130
+7,586
+8% +$1.03M 1.79% 18
2019
Q1 		$13.4M Sell
92,544
-2,435
-3% -$320K 1.77% 18
2018
Q4 		$10.8M Sell
94,979
-973
-1% -$122K 1.68% 21
2018
Q3 		$12.9M Sell
95,952
-1,152
-1% -$142K 1.69% 17
2018
Q2 		$10.9M Sell
97,104
-2,439
-2% -$264K 1.59% 24
2018
Q1 		$10.6M Sell
99,543
-752
-0.7% -$81.1K 1.55% 22
2017
Q4 		$11M Buy
100,295
+1,413
+1% +$154K 1.6% 19
2017
Q3 		$10.7M Buy
98,882
+577
+0.6% +$59.3K 1.66% 16
2017
Q2 		$9.94M Buy
98,305
+5,120
+5% +$471K 1.67% 13
2017
Q1 		$8.38M Buy
93,185
+9,485
+11% +$806K 1.57% 15
2016
Q4 		$6.38M Buy
83,700
+285
+0.3% +$21.6K 1.26% 33
2016
Q3 		$6.95M Buy
83,415
+43,625
+110% +$3.66M 1.45% 27
2016
Q2 		$3.28M Buy
39,790
+4,425
+13% +$364K 0.71% 51
2016
Q1 		$2.69M Buy
+35,365
New +$2.62M 0.56% 54

Other funds holding CRL

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
Harris Associates
Harris Associates Chicago, Illinois $75B AUM 11.27% 1-Year Est. Return
Allspring Global Investments
Allspring Global Investments Charlotte, North Carolina $59.7B AUM 29.08% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Norris Perne & French's CRL Position: Q1 2026 in Review

Norris Perne & French sold out of Charles River Laboratories (CRL) in Q1 2026, closing a stake of 5,475 shares — an estimated $1.09M sold.

Norris Perne & French first reported a position in CRL in Q1 2016 and held it in 40 quarters. The position peaked at $34.9M in Q1 2024. 558 funds tracked by Wall St. Rank hold CRL as of Q1 2026.

  • Norris Perne & French reported no remaining Charles River Laboratories position as of Q1 2026 after selling out during the quarter.
  • Norris Perne & French sold 5,475 Charles River Laboratories shares in Q1 2026, an estimated $1.09M.
  • Norris Perne & French first reported a position in Charles River Laboratories in Q1 2016 and held it in 40 quarters.
  • Norris Perne & French's Charles River Laboratories position peaked at $34.9M in Q1 2024.
  • 558 funds tracked by Wall St. Rank held Charles River Laboratories as of Q1 2026.

Based on Norris Perne & French's 13F filing for Q1 2026, filed 22 Apr 2026.